Struggling Arca gets Nasdaq warning

Just a week after its auditors offered a going-concern red flag, Arca biopharma says that Nasdaq has issued a warning on its failure to meet the market's minimum financial threshold. The Denver Business Journal reported a few days ago that Arca reported to the SEC recently that it only has enough cash to get through the first half of this year. And it's struggling to raise cash to finance a big trial of its lead therapy, which was demanded by the FDA last year. Arca is considering its strategic options, including a possible M&A deal. ARCA release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.